Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBP511 Sarbecovirus Vaccine in Healthy Adults
NCT07280858Phase 2Active, not recruiting
- Sponsor
- SK bioscience
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GBP511 in Sarbecovirus infection, sponsored by SK bioscience. Started Jan 2026; status: active, not recruiting.
02
Drugs
GBP511
03
Conditions
Sarbecovirus infection
Beyond the preview
Go deeper on NCT07280858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07280858.